It can intensify nausea, interact with blood glucose regulation, and provides empty calories that may impede weight loss goals
Anderson, MD, MAS, an assistant professor of medicine from the University of Pittsburgh, clinical trials of several GLP-1 receptor agonists like semaglutide (Wegovy/Ozempic, Novo Nordisk) for weight loss included exclusion criteria of chronic medical and psychiatric conditions. However, [FDA] labeling does not restrict these treatments in these populations, they wrote in JAMA Internal Medicine
High costs erode satisfaction
Start a private and secure instant message with a Well Revolution doctor right here from your phone or desktop
Carnitine deficiency in epileptic children treated with a diversity of anti-epileptic regimens
But TRT alone is not a powerful weight loss tool